報價延遲最少15分鐘:2025/09/04 07:52 EDT
盤前時段
|
||||
|
430 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-12.65/2.94
|
|
企業價值
9.84B
|
| 資產負債 |
|
每股賬面淨值
31.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
180.13M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 07:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
